

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Botanix Pharmaceuticals Limited
ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Vincent Ippolito
Date of last notice	04/01/2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Mr Ippolito is a trustee of the Ippolito Trust
Date of change	20/03/2023
No. of securities held prior to change Vincent Peter Ippolito Vincent Peter Ippolito and Karen Ann Ippolito <The Ippolito Trust>	6,801,644 Ordinary Shares 12,000,000 Unlisted Options exercisable at \$0.251 expiring 18 July 2023 6,000,000 Performance rights 3,000,000 Unlisted Options exercisable at \$0.115 expiring 23 May 2023
Class	Ordinary Shares Performance Rights
Number acquired	2,000,000 Ordinary Shares
Number disposed	2,000,000 Performance Rights

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after the change Vincent Peter Ippolito Vincent Peter Ippolito and Karen Ann Ippolito <The Ippolito Trust>	8,801,644 Ordinary Shares 12,000,000 Unlisted Options exercisable at \$0.251 expiring 18 July 2023 4,000,000 Performance rights 3,000,000 Unlisted Options exercisable at \$0.115 expiring 23 May 2023
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Performance Rights

Part 2 – Change of director’s interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Botanix Pharmaceuticals Limited
ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Matthew Callahan
Date of last notice	04/01/2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Shenasaby Pty Ltd < Shenasaby Trust> (Mr Callahan is a beneficiary of this trust)
Date of change	20/03/2023
No. of securities held prior to change	Shenasaby Pty Ltd < Shenasaby Trust> 72,253,458 Ordinary Shares 3,500,000 Performance Rights
Class	Ordinary Shares Performance Rights
Number acquired	1,166,666 Ordinary Shares
Number disposed	1,166,666 Performance Rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	Shenasaby Pty Ltd < Shenasaby Trust> 73,420,124 Ordinary Shares 2,333,334 Performance Rights

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Performance Rights
---	--------------------------------

Part 2 – Change of director's interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Botanix Pharmaceuticals Limited
ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr H. William Bosch
Date of last notice	04/01/2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	20/03/2023
No. of securities held prior to change	17,836,702 Ordinary Shares 1,500,000 Performance Rights
Class	Ordinary Shares Performance Rights
Number acquired	500,000 Ordinary Shares
Number disposed	500,000 Performance Rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	18,336,702 Ordinary Shares 1,000,000 Performance Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Performance Rights

Part 2 – Change of director's interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Botanix Pharmaceuticals Limited
ACN	009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Stewart Washer
Date of last notice	04/01/2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (Including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Dr Stewart James Washer & Dr Patrizia Derna Washer as trustee for the Washer Family Trust (Dr Washer is a trustee and beneficiary of the trust) Mal Washer Nominees Pty Ltd (Dr Washer is a director of the company)

Date of change	20/03/2023
No. of securities held prior to change Dr Stewart James Washer & Dr Patrizia Derna Washer as trustee for the Washer Family Trust Mal Washer Nominees Pty Ltd	321,551 Ordinary Shares 5,000,000 Unlisted Options exercisable at 0.102 each, expiring 22 March 2025 1,000,000 Performance Rights 1,515,151 Ordinary Shares
Class	Ordinary Shares Performance Rights

+ See chapter 19 for defined terms.

Number acquired	333,333 Ordinary Shares
Number disposed	333,333 Performance Rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change Dr Stewart James Washer & Dr Patrizia Derna Washer as trustee for the Washer Family Trust Mal Washer Nominees Pty Ltd	654,884 Ordinary Shares 5,000,000 Unlisted Options exercisable at 0.102 each, expiring 22 March 2025 666,667 Performance Rights 1,515,151 Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Performance Rights

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Botanix Pharmaceuticals Limited
ACN	009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Daniel Sharp
Date of last notice	04/01/2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	DJMB Corporate Pty Ltd (Mr Sharp is a director of DJMB Corporate Pty Ltd)
Date of change	20/3/2023
No. of securities held prior to change DJMB Corporate Pty Ltd	1,515,151 Ordinary Shares 1,000,000 Unlisted Options exercisable at 0.071 each, expiring 22 March 2022 4,000,000 Unlisted Options exercisable at 0.094 each, expiring 22 March 2025 and vesting progressively over three years 1,000,000 Performance Rights
Class	Ordinary Shares Performance Rights Unlisted Options

+ See chapter 19 for defined terms.

Number acquired	616,162 Ordinary Shares
Number disposed	333,333 Performance Rights 1,000,000 Unlisted Options exercisable at 0.071 each, expiring 22 March 2022
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change DJMB Corporate Pty Ltd	2,131,313 Ordinary Shares 4,000,000 Unlisted Options exercisable at 0.094 each, expiring 22 March 2025 and vesting progressively over three years 666,667 Performance Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Performance Rights and Unlisted Options

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 Closed Period

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.